150 related articles for article (PubMed ID: 37193776)
1. ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer - an interim analysis.
Tutrone R; Lowentritt B; Neuman B; Donovan MJ; Hallmark E; Cole TJ; Yao Y; Biesecker C; Kumar S; Verma V; Sant GR; Alter J; Skog J
Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):596-601. PubMed ID: 37193776
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10 ng/mL.
Tutrone R; Donovan MJ; Torkler P; Tadigotla V; McLain T; Noerholm M; Skog J; McKiernan J
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):607-614. PubMed ID: 32382078
[TBL] [Abstract][Full Text] [Related]
3. Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies.
Margolis E; Brown G; Partin A; Carter B; McKiernan J; Tutrone R; Torkler P; Fischer C; Tadigotla V; Noerholm M; Donovan MJ; Skog J
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):296-301. PubMed ID: 34593984
[TBL] [Abstract][Full Text] [Related]
4. Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome.
Kretschmer A; Tutrone R; Alter J; Berg E; Fischer C; Kumar S; Torkler P; Tadigotla V; Donovan M; Sant G; Skog J; Noerholm M
World J Urol; 2022 Apr; 40(4):983-989. PubMed ID: 35084544
[TBL] [Abstract][Full Text] [Related]
5. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
[TBL] [Abstract][Full Text] [Related]
6. A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy.
McKiernan J; Noerholm M; Tadigotla V; Kumar S; Torkler P; Sant G; Alter J; Donovan MJ; Skog J
BMC Urol; 2020 Sep; 20(1):138. PubMed ID: 32873277
[TBL] [Abstract][Full Text] [Related]
7. Utility of noninvasive biomarker testing and MRI to predict a prostate cancer diagnosis.
Sultan MI; Huynh LM; Kamil S; Abdelaziz A; Hammad MA; Gin GE; Lee DI; Youssef RF
Int Urol Nephrol; 2024 Feb; 56(2):539-546. PubMed ID: 37742327
[TBL] [Abstract][Full Text] [Related]
8. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
[TBL] [Abstract][Full Text] [Related]
9. How I Use It: The Exosome Diagnostics (EPI) prostate cancer biomarker utility in urology and primary care.
Moul JW; Sant GR
Can J Urol; 2022 Aug; 29(4):11224-11230. PubMed ID: 35969726
[TBL] [Abstract][Full Text] [Related]
10. Validation of a CE-IVD, urine exosomal RNA expression assay for risk assessment of prostate cancer prior to biopsy.
Kretschmer A; Kajau H; Margolis E; Tutrone R; Grimm T; Trottmann M; Stief C; Stoll G; Fischer CA; Flinspach C; Albrecht A; Meyer L; Priewasser T; Enderle D; Müller R; Torkler P; Alter J; Skog J; Noerholm M
Sci Rep; 2022 Mar; 12(1):4777. PubMed ID: 35314720
[TBL] [Abstract][Full Text] [Related]
11. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of multiple secondary combined tests in prostate cancer screening.
Dudinec JV; Wang SM; Kotamarti S; Morris KE; Polascik TJ; Moul JW
Can J Urol; 2023 Jun; 30(3):11538-11544. PubMed ID: 37344464
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
14. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of the relationship between PI-RADS scores and the pathological results of targeted biopsy based on MRI].
Wang YM; Shang JW; Dong L; Liang LH; Zhao RZ; Liang C; Wang SQ; Xia W; Cheng G; Hua LX
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):942-947. PubMed ID: 37968079
[No Abstract] [Full Text] [Related]
16. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.
Beard CJ; Chen MH; Cote K; Loffredo M; Renshaw AA; Hurwitz M; D'Amico AV
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):19-24. PubMed ID: 14697416
[TBL] [Abstract][Full Text] [Related]
17. Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up.
Klotz L; Pond G; Loblaw A; Sugar L; Moussa M; Berman D; Van der Kwast T; Vesprini D; Milot L; Kebabdjian M; Fleshner N; Ghai S; Chin J; Haider M
Eur Urol; 2020 Mar; 77(3):311-317. PubMed ID: 31708295
[TBL] [Abstract][Full Text] [Related]
18. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial.
Pollack A; Zagars GK; Antolak JA; Kuban DA; Rosen II
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):677-85. PubMed ID: 12377318
[TBL] [Abstract][Full Text] [Related]
19. The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate.
Kohestani K; Månsson M; Arnsrud Godtman R; Stranne J; Wallström J; Carlsson S; Hellström M; Hugosson J
Scand J Urol; 2021 Apr; 55(2):116-124. PubMed ID: 33612068
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
